CRLCharles River Laboratories
Price
+92%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, price roughly fair, growth steady, the market undecided.
We are a leading, full service, non-clinical global drug development partner with a mission to create healthier lives. We have built upon our original core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports our clients from target identification through non-clinical development.
In the company’s own words · 10-K filed Feb 18, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Charles River Laboratories (CRL) reported revenue of $1.00B in Q2 2026 (quarter ended Jun 27, 2026), down 2.7% from the same quarter a year earlier. That came with net loss of $1.5M. For the full year FY2025, revenue was $4.02B (−0.9% year on year) and net income −$144M. Its largest segment in Q2 2026 was Discovery And Safety Assessment at $606M, 77% of the disclosed total, well ahead of Research Models And Services at 12%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- May 11, 2026On May 5, 2026, Charles River Laboratories International, Inc. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”)Director or officer change · Form 8-K
- Feb 18, 2026On February 18, 2026, the Company announced the appointment of Glenn Coleman as its Corporate Executive Vice President and Chief Financial Officer.Director or officer change · Form 8-K
- Jan 9, 2026Chief Executive Officer Transition On January 8, 2026, the Board of Directors (the “Board”) of Charles River Laboratories International, Inc. (the “Company”) announced a leadership transition plan.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $785.2MThe company’s own SEC segment disclosure.
- Discovery And Safety Assessment$605.9M77%
- Research Models And Services$94.4M12%
- Manufacturing Support$84.9M11%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
The closest names by size in the same industry